232 related articles for article (PubMed ID: 30799654)
61. Enhanced antitumor efficacy of gemcitabine-loaded temperature-sensitive liposome by hyperthermia in tumor-bearing mice.
Lim SK; Shin DH; Choi MH; Kim JS
Drug Dev Ind Pharm; 2014 Apr; 40(4):470-6. PubMed ID: 23614830
[TBL] [Abstract][Full Text] [Related]
62. Eradication of osteosarcoma lung metastasis using intranasal gemcitabine.
Jia SF; Worth LL; Turan M; Duan Xp XP; Kleinerman ES
Anticancer Drugs; 2002 Feb; 13(2):155-61. PubMed ID: 11901308
[TBL] [Abstract][Full Text] [Related]
63. Development of high-content gemcitabine PEGylated liposomes and their cytotoxicity on drug-resistant pancreatic tumour cells.
Xu H; Paxton J; Lim J; Li Y; Zhang W; Duxfield L; Wu Z
Pharm Res; 2014 Oct; 31(10):2583-92. PubMed ID: 24639234
[TBL] [Abstract][Full Text] [Related]
64. Enhanced anticancer effect of gemcitabine by genistein in osteosarcoma: the role of Akt and nuclear factor-kappaB.
Zhang B; Shi ZL; Liu B; Yan XB; Feng J; Tao HM
Anticancer Drugs; 2010 Mar; 21(3):288-96. PubMed ID: 20038829
[TBL] [Abstract][Full Text] [Related]
65. Enhancement of Pancreatic Cancer Therapy Efficacy by Type-1 Matrix Metalloproteinase-Functionalized Nanoparticles for the Selective Delivery of Gemcitabine and Erlotinib.
Yin N; Yu H; Zhang X; Lv X
Drug Des Devel Ther; 2020; 14():4465-4475. PubMed ID: 33122890
[TBL] [Abstract][Full Text] [Related]
66. Synthesis of a gemcitabine-modified phospholipid and its subsequent incorporation into a single microbubble formulation loaded with paclitaxel for the treatment of pancreatic cancer using ultrasound-targeted microbubble destruction.
Logan KA; Nesbitt H; Callan B; Gao J; McKaig T; Taylor M; Love M; McHale AP; Callan JF
Eur J Pharm Biopharm; 2021 Aug; 165():374-382. PubMed ID: 34038797
[TBL] [Abstract][Full Text] [Related]
67. Nanoformulation of Apolipoprotein E3-Tagged Liposomal Nanoparticles for the co-Delivery of KRAS-siRNA and Gemcitabine for Pancreatic Cancer Treatment.
Wang F; Zhang Z
Pharm Res; 2020 Nov; 37(12):247. PubMed ID: 33216236
[TBL] [Abstract][Full Text] [Related]
68. Gambogic acid potentiates gemcitabine induced anticancer activity in non-small cell lung cancer.
Hatami E; Nagesh PKB; Jaggi M; Chauhan SC; Yallapu MM
Eur J Pharmacol; 2020 Dec; 888():173486. PubMed ID: 32805254
[TBL] [Abstract][Full Text] [Related]
69. Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.
Awasthi N; Zhang C; Hinz S; Schwarz MA; Schwarz RE
J Exp Clin Cancer Res; 2013 Mar; 32(1):12. PubMed ID: 23497499
[TBL] [Abstract][Full Text] [Related]
70. BSA-PLGA-based core-shell nanoparticles as carrier system for water-soluble drugs.
Chitkara D; Kumar N
Pharm Res; 2013 Sep; 30(9):2396-409. PubMed ID: 23756758
[TBL] [Abstract][Full Text] [Related]
71. Co-delivery of gemcitabine and cisplatin via Poly (L-glutamic acid)-g-methoxy poly (ethylene glycol) micelle to improve the in vivo stability and antitumor effect.
Ding N; Zhao Z; Yin N; Xu Y; Yin T; Gou J; He H; Wang Y; Zhang Y; Tang X
Pharm Res; 2021 Dec; 38(12):2091-2108. PubMed ID: 34893950
[TBL] [Abstract][Full Text] [Related]
72. Aerosol therapy for the treatment of osteosarcoma lung metastases: targeting the Fas/FasL pathway and rationale for the use of gemcitabine.
Gordon N; Kleinerman ES
J Aerosol Med Pulm Drug Deliv; 2010 Aug; 23(4):189-96. PubMed ID: 20528149
[TBL] [Abstract][Full Text] [Related]
73. Coaxial mussel-inspired biofibers: making of a robust and efficacious depot for cancer drug delivery.
Talebian S; Shim IK; Kim SC; Spinks GM; Vine KL; Foroughi J
J Mater Chem B; 2020 Jun; 8(23):5064-5079. PubMed ID: 32400836
[TBL] [Abstract][Full Text] [Related]
74. Molecularly targeted gemcitabine-loaded nanoparticulate system towards the treatment of EGFR overexpressing lung cancer.
Wang XB; Zhou HY
Biomed Pharmacother; 2015 Mar; 70():123-8. PubMed ID: 25776490
[TBL] [Abstract][Full Text] [Related]
75. Enzyme-responsive peptide dendrimer-gemcitabine conjugate as a controlled-release drug delivery vehicle with enhanced antitumor efficacy.
Zhang C; Pan D; Li J; Hu J; Bains A; Guys N; Zhu H; Li X; Luo K; Gong Q; Gu Z
Acta Biomater; 2017 Jun; 55():153-162. PubMed ID: 28259838
[TBL] [Abstract][Full Text] [Related]
76. Bitter melon juice intake with gemcitabine intervention circumvents resistance to gemcitabine in pancreatic patient-derived xenograft tumors.
Dhar D; Raina K; Kumar D; Wempe MF; Bagby SM; Pitts TM; Orlicky DJ; Agarwal C; Messersmith WA; Agarwal R
Mol Carcinog; 2020 Oct; 59(10):1227-1240. PubMed ID: 32816368
[TBL] [Abstract][Full Text] [Related]
77. S-Adenosylmethionine synergistically enhances the antitumor effect of gemcitabine against pancreatic cancer through JAK2/STAT3 pathway.
Liu Y; Bi T; Liu L; Gao Q; Shen G; Qin L
Naunyn Schmiedebergs Arch Pharmacol; 2019 May; 392(5):615-622. PubMed ID: 30683944
[TBL] [Abstract][Full Text] [Related]
78. AS1411 Aptamer-Decorated Biodegradable Polyethylene Glycol-Poly(lactic-co-glycolic acid) Nanopolymersomes for the Targeted Delivery of Gemcitabine to Non-Small Cell Lung Cancer In Vitro.
Alibolandi M; Ramezani M; Abnous K; Hadizadeh F
J Pharm Sci; 2016 May; 105(5):1741-1750. PubMed ID: 27039356
[TBL] [Abstract][Full Text] [Related]
79. Genistein potentiates the anti-cancer effects of gemcitabine in human osteosarcoma via the downregulation of Akt and nuclear factor-κB pathway.
Liang C; Li H; Shen C; Lai J; Shi Z; Liu B; Tao HM
Anticancer Agents Med Chem; 2012 Jun; 12(5):554-63. PubMed ID: 22263786
[TBL] [Abstract][Full Text] [Related]
80. In vivo drug delivery of gemcitabine with PEGylated single-walled carbon nanotubes.
Razzazan A; Atyabi F; Kazemi B; Dinarvand R
Mater Sci Eng C Mater Biol Appl; 2016 May; 62():614-25. PubMed ID: 26952465
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]